NEW ORLEANS, May 2, 2013 /PRNewswire/ -- Ferring Pharmaceuticals will present efficacy and safety data from its Phase 3 EXPEDITE* study for its investigational controlled release misoprostol vaginal insert (MVI) at the 61st annual clinical meeting of the American College of Obstetricians and Gynecologists in New Orleans, May 4 – 8, 2013.
Studies accepted for presentation include:
- A poster presentation on Tues., May 7 (3:00 p.m. – 4:00 p.m. EDT), titled "Reduced Time to Delivery and Significantly Less Antibiotic Use" (lead author: Deborah A. Wing, M.D.; University of California, Irvine; Irvine, CA); and
- A poster presentation on Tues., May 7 (3:00 p.m. – 4:00 p.m. EDT), titled "Misoprostol Vaginal Insert Reduces Time to Delivery in Nulliparous and Parous Women" (lead author: R. Lamar Parker, M.D.; Lyndhurst Clinical Research, Winston-Salem, NC).
*The EXPEDITE Study: A Phase 3, double blind, randomized, multicenter study of EXogenous Prostaglandin comparing the Efficacy and safety of the MVI 200 mcg to the Dinoprostone vaginal Insert for reducing Time to vaginal delivery in pregnant women at tErm.
For further information, contact:
MSL New York
About Ferring Pharmaceuticals:
Ferring Pharmaceuticals is a research-driven speciality biopharmaceutical company, active in global markets. The company identifies, develops and markets innovative products in the areas of general and pediatric endocrinology, gastroenterology, infertility, obstetrics/gynecology, orthopedics and urology. For more information, call 1-888-FERRING (1-888-337-7464) or visit www.FerringUSA.com.
SOURCE Ferring Pharmaceuticals